00:00The PROC has come to the following conclusions.
00:03This vaccine is safe and effective in preventing COVID-19
00:08and its benefits continue to be far greater than its risks.
00:13PROC has found no evidence of a quality or a batch issue.
00:19The committee has assessed and discussed preclinical and clinical trial data,
00:24published literature and adverse events related to the blood clots
00:29that have occurred during the vaccination campaign,
00:33reported by vaccinees and healthcare professionals.
00:38Critical to the review has been the careful scientific assessment
00:42and clinical scrutiny of the individual cases from the different member states.
00:49PROC noted that the number of thromboembolic events
00:53reported after vaccination is lower than the expected in the general population
00:58and PROC has concluded that there is no increase
01:02in the overall risk of blood clots with this vaccine.
Commenti